<?xml version='1.0' encoding='utf-8'?>
<document id="10972481"><sentence text="Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens."><entity charOffset="13-29" id="DDI-PubMed.10972481.s1.e0" text="cyclophosphamide" /></sentence><sentence text="Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens"><entity charOffset="0-16" id="DDI-PubMed.10972481.s2.e0" text="Cyclophosphamide" /><entity charOffset="21-29" id="DDI-PubMed.10972481.s2.e1" text="thioTEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s2.e0" e2="DDI-PubMed.10972481.s2.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s2.e0" e2="DDI-PubMed.10972481.s2.e1" /></sentence><sentence text=" During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin, a sharp decrease in 4-hydroxycyclophosphamide concentration was observed immediately after the start of the thioTEPA infusion"><entity charOffset="64-80" id="DDI-PubMed.10972481.s3.e0" text="cyclophosphamide" /><entity charOffset="110-135" id="DDI-PubMed.10972481.s3.e1" text="4-hydroxycyclophosphamide" /><entity charOffset="187-198" id="DDI-PubMed.10972481.s3.e2" text="carboplatin" /><entity charOffset="220-245" id="DDI-PubMed.10972481.s3.e3" text="4-hydroxycyclophosphamide" /><entity charOffset="308-316" id="DDI-PubMed.10972481.s3.e4" text="thioTEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e0" e2="DDI-PubMed.10972481.s3.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e0" e2="DDI-PubMed.10972481.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e0" e2="DDI-PubMed.10972481.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e0" e2="DDI-PubMed.10972481.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e0" e2="DDI-PubMed.10972481.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e1" e2="DDI-PubMed.10972481.s3.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e1" e2="DDI-PubMed.10972481.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e1" e2="DDI-PubMed.10972481.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e1" e2="DDI-PubMed.10972481.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e2" e2="DDI-PubMed.10972481.s3.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e2" e2="DDI-PubMed.10972481.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e2" e2="DDI-PubMed.10972481.s3.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e3" e2="DDI-PubMed.10972481.s3.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s3.e3" e2="DDI-PubMed.10972481.s3.e4" /></sentence><sentence text=" A drug-drug interaction was suspected" /><sentence text=" This putative interaction was investigated in this study" /><sentence text="" /><sentence text="Possible sequence dependency, due to inhibition of the formation of 4-hydroxycyclophosphamide by thioTEPA, was investigated by altering the sequence of infusion in three patients (four courses) receiving high-dose chemotherapy with cyclophosphamide (1,000 or 1,500 mg/m2 per day), thioTEPA (80 or 120 mg/m2 per day) and carboplatin (265 or 400 mg/m2 per day) in short infusions for four consecutive days"><entity charOffset="68-93" id="DDI-PubMed.10972481.s7.e0" text="4-hydroxycyclophosphamide" /><entity charOffset="97-105" id="DDI-PubMed.10972481.s7.e1" text="thioTEPA" /><entity charOffset="232-248" id="DDI-PubMed.10972481.s7.e2" text="cyclophosphamide" /><entity charOffset="281-289" id="DDI-PubMed.10972481.s7.e3" text="thioTEPA" /><entity charOffset="320-331" id="DDI-PubMed.10972481.s7.e4" text="carboplatin" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e0" e2="DDI-PubMed.10972481.s7.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e0" e2="DDI-PubMed.10972481.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e0" e2="DDI-PubMed.10972481.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e0" e2="DDI-PubMed.10972481.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e0" e2="DDI-PubMed.10972481.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e1" e2="DDI-PubMed.10972481.s7.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e1" e2="DDI-PubMed.10972481.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e1" e2="DDI-PubMed.10972481.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e1" e2="DDI-PubMed.10972481.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e2" e2="DDI-PubMed.10972481.s7.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e2" e2="DDI-PubMed.10972481.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e2" e2="DDI-PubMed.10972481.s7.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e3" e2="DDI-PubMed.10972481.s7.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s7.e3" e2="DDI-PubMed.10972481.s7.e4" /></sentence><sentence text=" The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were established"><entity charOffset="25-41" id="DDI-PubMed.10972481.s8.e0" text="cyclophosphamide" /><entity charOffset="46-71" id="DDI-PubMed.10972481.s8.e1" text="4-hydroxycyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.10972481.s8.e0" e2="DDI-PubMed.10972481.s8.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s8.e0" e2="DDI-PubMed.10972481.s8.e1" /></sentence><sentence text=" Possible inhibition of the metabolism of cyclophosphamide and thioTEPA was investigated in human microsomes"><entity charOffset="42-58" id="DDI-PubMed.10972481.s9.e0" text="cyclophosphamide" /><entity charOffset="63-71" id="DDI-PubMed.10972481.s9.e1" text="thioTEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s9.e0" e2="DDI-PubMed.10972481.s9.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s9.e0" e2="DDI-PubMed.10972481.s9.e1" /></sentence><sentence text="" /><sentence text="A striking sequence dependency of the pharmacokinetics of 4-hydroxycyclophosphamide was observed"><entity charOffset="58-83" id="DDI-PubMed.10972481.s11.e0" text="4-hydroxycyclophosphamide" /></sentence><sentence text=" Administration of thioTEPA 1 h prior to cyclophosphamide resulted in decreased Cmax (-62%) and AUC (-26%) values of 4-hydroxycyclophosphamide compared to those of thioTEPA administered 1 h after cyclophosphamide"><entity charOffset="19-27" id="DDI-PubMed.10972481.s12.e0" text="thioTEPA" /><entity charOffset="41-57" id="DDI-PubMed.10972481.s12.e1" text="cyclophosphamide" /><entity charOffset="117-142" id="DDI-PubMed.10972481.s12.e2" text="4-hydroxycyclophosphamide" /><entity charOffset="164-172" id="DDI-PubMed.10972481.s12.e3" text="thioTEPA" /><entity charOffset="196-212" id="DDI-PubMed.10972481.s12.e4" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e0" e2="DDI-PubMed.10972481.s12.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e0" e2="DDI-PubMed.10972481.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e0" e2="DDI-PubMed.10972481.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e0" e2="DDI-PubMed.10972481.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e0" e2="DDI-PubMed.10972481.s12.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e1" e2="DDI-PubMed.10972481.s12.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e1" e2="DDI-PubMed.10972481.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e1" e2="DDI-PubMed.10972481.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e1" e2="DDI-PubMed.10972481.s12.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e2" e2="DDI-PubMed.10972481.s12.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e2" e2="DDI-PubMed.10972481.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e2" e2="DDI-PubMed.10972481.s12.e4" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e3" e2="DDI-PubMed.10972481.s12.e3" /><pair ddi="false" e1="DDI-PubMed.10972481.s12.e3" e2="DDI-PubMed.10972481.s12.e4" /></sentence><sentence text=" In human microsomes an inhibition of the conversion of cyclophosphamide to 4-hydroxycyclophosphamide by thioTEPA was observed at clinically relevant concentrations with an IC50 of 23 microM"><entity charOffset="56-72" id="DDI-PubMed.10972481.s13.e0" text="cyclophosphamide" /><entity charOffset="76-101" id="DDI-PubMed.10972481.s13.e1" text="4-hydroxycyclophosphamide" /><entity charOffset="105-113" id="DDI-PubMed.10972481.s13.e2" text="thioTEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s13.e0" e2="DDI-PubMed.10972481.s13.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s13.e0" e2="DDI-PubMed.10972481.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s13.e0" e2="DDI-PubMed.10972481.s13.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s13.e1" e2="DDI-PubMed.10972481.s13.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s13.e1" e2="DDI-PubMed.10972481.s13.e2" /></sentence><sentence text=" No inhibition of the formation of TEPA by cyclophosphamide was observed"><entity charOffset="35-39" id="DDI-PubMed.10972481.s14.e0" text="TEPA" /><entity charOffset="43-59" id="DDI-PubMed.10972481.s14.e1" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.10972481.s14.e0" e2="DDI-PubMed.10972481.s14.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s14.e0" e2="DDI-PubMed.10972481.s14.e1" /></sentence><sentence text="" /><sentence text="ThioTEPA strongly inhibits the bioactivation of cyclophosphamide and this may decrease both efficacy and toxicity"><entity charOffset="0-8" id="DDI-PubMed.10972481.s16.e0" text="ThioTEPA" /><entity charOffset="48-64" id="DDI-PubMed.10972481.s16.e1" text="cyclophosphamide" /><entity charOffset="4-19" id="DDI-PubMed.10972481.s16.e2" text="TEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s16.e0" e2="DDI-PubMed.10972481.s16.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s16.e0" e2="DDI-PubMed.10972481.s16.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s16.e0" e2="DDI-PubMed.10972481.s16.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s16.e2" e2="DDI-PubMed.10972481.s16.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s16.e2" e2="DDI-PubMed.10972481.s16.e1" /></sentence><sentence text=" Our results seriously question the practice of the simultaneous continuous infusion of cyclophosphamide and thioTEPA and suggest that the sequencing and scheduling of these two agents in high-dose chemotherapy regimens may be of critical importance"><entity charOffset="88-104" id="DDI-PubMed.10972481.s17.e0" text="cyclophosphamide" /><entity charOffset="109-117" id="DDI-PubMed.10972481.s17.e1" text="thioTEPA" /><entity charOffset="113-120" id="DDI-PubMed.10972481.s17.e2" text="TEPA" /><pair ddi="false" e1="DDI-PubMed.10972481.s17.e0" e2="DDI-PubMed.10972481.s17.e0" /><pair ddi="false" e1="DDI-PubMed.10972481.s17.e0" e2="DDI-PubMed.10972481.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s17.e0" e2="DDI-PubMed.10972481.s17.e2" /><pair ddi="false" e1="DDI-PubMed.10972481.s17.e1" e2="DDI-PubMed.10972481.s17.e1" /><pair ddi="false" e1="DDI-PubMed.10972481.s17.e1" e2="DDI-PubMed.10972481.s17.e2" /></sentence><sentence text="" /></document>